ZPL 5212372

Drug Profile

ZPL 5212372

Alternative Names: PF-05212372; PF-5212372; PLA-950; ZPL-521; ZPL-5212372

Latest Information Update: 28 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer Pfizer; Ziarco
  • Class Antiasthmatics
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis
  • No development reported Psoriasis
  • Discontinued Asthma

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Psoriasis(In volunteers) in United Kingdom (Topical)
  • 01 Mar 2017 Ziarco completes a phase I/II trial in Atopic dermatitis in United Kingdom (NCT02795832)
  • 01 Jun 2016 Phase-I/II clinical trials in Atopic dermatitis in United Kingdom (Topical) (NCT02795832)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top